Categories
Prostate cancer

Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study

  • Bray F, Lortet-Tieulent J, Ferlay J, Forman D, Auvinen A. Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer. 2010;46:3040–52.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737–46.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377:352–60.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381:121–31.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381:13–24.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147–54.

    Article 
    PubMed 

    Google Scholar
     

  • Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138–48.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–97.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–33.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fosså SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091–103.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Petrylak DP, Loriot Y, Shaffer DR, Braiteh F, Powderly J, Harshman LC, et al. Safety and clinical activity of atezolizumab in patients with metastatic castration-resistant prostate cancer: a phase I study. Clin Cancer Res. 2021;27:3360–9.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Hansen AR, Massard C, Ott PA, Haas NB, Lopez JS, Ejadi S, et al. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Ann Oncol. 2018;29:1807–13.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Antonarakis ES, Piulats JM, Gross-Goupil M, Goh J, Ojamaa K, Hoimes CJ, et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol. 2020;38:395–405.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Palicelli A, Croci S, Bisagni A, Zanetti E, De Biase D, Melli B, et al. What do we have to know about PD-L1 expression in prostate cancer? A systematic literature review. Part 3: PD-L1, intracellular signaling pathways and tumor microenvironment. Int J Mol Sci. 2021;22:12297.

  • Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–22.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Fizazi K, Drake CG, Beer TM, Kwon ED, Scher HI, Gerritsen WR, et al. Final analysis of the ipilimumab versus placebo following radiotherapy phase III trial in postdocetaxel metastatic castration-resistant prostate cancer identifies an excess of long-term survivors. Eur Urol. 2020;78:822–30.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Bracci L, Schiavoni G, Sistigu A, Belardelli F. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ. 2014;21:15–25.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Rodríguez-Abreu D, Powell SF, Hochmair MJ, Gadgeel S, Esteban E, Felip E, et al. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Ann Oncol. 2021;32:881–95.

    Article 
    PubMed 

    Google Scholar
     

  • Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022;386:449–62.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016;34:1402–18.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. (v4.03: June 14, 2010). https://www.eortc.be/services/doc/ctc/ctcae_4.03_2010-06-14_quickreference_5x7.pdf. Accessed February 2022.

  • Fizazi K, González Mella P, Castellano D, Minatta JN, Rezazadeh Kalebasty A, Shaffer D, et al. Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial. Eur J Cancer. 2022;160:61–71.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Fizazi K, González Mella P, Castellano D, Minatta JN, Rezazadeh A, Shaffer DR, et al. CheckMate 9KD arm B final analysis: efficacy and safety of nivolumab plus docetaxel for chemotherapy-naïve metastatic castration-resistant prostate cancer. J Clin Oncol. 2021;39.6(suppl):12.

  • Powles T, Yuen KC, Gillessen S, Kadel EE, Rathkopf D, Matsubara N, et al. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nat Med. 2022;28:144–53.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Graff JN, Beer TM, Alumkal JJ, Slottke RE, Redmond WL, Thomas GV, et al. A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone. J Immunother Cancer. 2020;8.

  • Hoimes CJ, Graff JN, Tagawa ST, Hwang C, Kilari D, Tije AJT, et al. KEYNOTE-199 cohorts 4 and 5: Phase II study of pembrolizumab plus enzalutamide for Enza-resistant metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2020;38(15_suppl):5543.

  • Shenderov E, Boudadi K, Fu W, Wang H, Sullivan R, Jordan A, et al. Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: a phase-2 nonrandomized clinical trial. Prostate. 2021;81:326–38.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Sharma P, Pachynski RK, Narayan V, Fléchon A, Gravis G, Galsky MD, et al. Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the CheckMate 650 trial. Cancer Cell. 2020;38:489–99.e3.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Agarwal N, McGregor BA, Maughan BL, Dorff T, Kelly W, Fang B, et al. Cabozantinib in combination with atezolizumab in patients with metastatic castration resistant prostate cancer mCRPC): results of expanded cohort 6 of the COSMIC 021 study. Ann Oncol. 2021;32:S1283–346.

  • Karzai F, VanderWeele D, Madan RA, Owens H, Cordes LM, Hankin A, et al. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. J Immunother Cancer. 2018;6:141.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Yu E, Piulats JM, Gravis G, Fong PC, Todenhöfer T, Laguerre B, et al. Pembrolizumab plus olaparib in patients with docetaxel-pretreated metastatic castration-resistant prostate cancer: update of KEYNOTE-365 cohort a with a minimum of 11 months of follow-up for all patients. Ann Oncol. 2021;32:S652–3.

    Article 

    Google Scholar
     

  • Petrylak DP, Perez-Gracia JL, Lacombe L, Bastos DA, Mahammedi H, Kwan EM, et al. CheckMate 9KD cohort A2 final analysis: nivolumab plus rucaparib for chemotherapy naïve metastatic castration resistant prostate cancer. Ann Oncol. 2021;32:S626–77.

    Article 

    Google Scholar
     

  • Fong L, Morris MJ, Sartor O, Higano CS, Pagliaro L, Alva A, et al. A phase Ib study of atezolizumab with radium-223 dichloride in men with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2021;27:4746–56.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Flieswasser T, Van Loenhout J, Freire Boullosa L, Van den Eynde A, De Waele J, Van Audenaerde J, et al. Clinically relevant chemotherapeutics have the ability to induce immunogenic cell death in non-small cell lung cancer. Cells. 2020;9:1474.

  • De Bono JS, Joshua AM, Shore ND, Kramer G, Tong Li X, Poehlein CH, et al. KEYNOTE-365 cohort I: phase 1b/2 study of pembrolizumab combined with platinum-containing chemotherapy and chemotherapy alone for treatment-emergent neuroendocrine prostate carcinoma (t-NE). J Clin Oncol. 2022;(suppl 6; abstr TPS218):40.

  • Zhang J, Shih DJH, Lin SY. Role of DNA repair defects in predicting immunotherapy response. Biomark Res. 2020;8:23.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Mota JM, Barnett E, Nauseef JT, Nguyen B, Stopsack KH, Wibmer A, et al. Platinum-based chemotherapy in metastatic prostate cancer with DNA repair gene alterations. JCO Precis Oncol. 2020;4:355–66.

    Article 
    PubMed 

    Google Scholar
     

  • Mateo J, Porta N, Bianchini D, McGovern U, Elliott T, Jones R, et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21:162–74.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Wu YM, Cieślik M, Lonigro RJ, Vats P, Reimers MA, Cao X, et al. Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate. Cancer Cell. 2018;173:1770–82.e14.

    CAS 

    Google Scholar
     

  • Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409–13.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Narayan V, Barber-Rotenberg J, Fraietta J, Hwang WT, Lacey SF, Plesa G, et al. A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer. J Clin Oncol. 2021;39:125–125.

    Article 

    Google Scholar
     

  • De Bono JS, Fong L, Beer TM, Gao X, Geynisman DM, Burris HA, et al. Results of an ongoing phase 1/2a dose escalation study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager, in patients with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2021;(suppl 15; abstr 5013):39.